Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 3
2008 2
2009 3
2010 5
2011 4
2012 4
2013 4
2014 3
2015 4
2016 9
2017 7
2018 5
2019 5
2020 6
2021 4
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Refractory Hodgkin lymphoma.
von Tresckow B, Engert A. von Tresckow B, et al. Curr Opin Oncol. 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. Curr Opin Oncol. 2013. PMID: 23942291 Review.
PURPOSE OF REVIEW: Despite the advances in the treatment of Hodgkin Lymphoma, patients with refractory disease still have a poor prognosis. Hodgkin Lymphoma can be refractory at first diagnosis or might become refractory later in the course of treatment. ...Brentuxi …
PURPOSE OF REVIEW: Despite the advances in the treatment of Hodgkin Lymphoma, patients with refractory disease still have a poor prognosi …
PET-adapted therapy for advanced Hodgkin lymphoma - systematic review.
Amitai I, Gurion R, Vidal L, Dann EJ, Raanani P, Gafter-Gvili A. Amitai I, et al. Acta Oncol. 2018 Jun;57(6):765-772. doi: 10.1080/0284186X.2018.1426877. Epub 2018 Jan 18. Acta Oncol. 2018. PMID: 29345517 Review.
INTRODUCTION: Positron emission tomography-computed tomography (PET-CT) performed after two chemotherapy cycles (PET-2) has become an accepted prognostic tool in Hodgkin lymphoma (HL). We evaluated the effect of PET-adapted strategy on outcome in advanced stage HL. ...
INTRODUCTION: Positron emission tomography-computed tomography (PET-CT) performed after two chemotherapy cycles (PET-2) has become an accept …
Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT.
Lynch RC, Advani RH. Lynch RC, et al. Am Soc Clin Oncol Educ Book. 2016;35:e376-85. doi: 10.1200/EDBK_159036. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249744 Free article. Review.
Retrospective studies show that a negative interim PET-CT after two to four cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is predictive of favorable outcome independent of IPS score. Currently, there are several ongoing trials that aim to determine whet …
Retrospective studies show that a negative interim PET-CT after two to four cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine …
Optimal therapy of advanced Hodgkin lymphoma.
Advani R. Advani R. Hematology Am Soc Hematol Educ Program. 2011;2011:310-6. doi: 10.1182/asheducation-2011.1.310. Hematology Am Soc Hematol Educ Program. 2011. PMID: 22160051 Review.
The incorporation of interim positron emission tomography (PET) imaging and, recently, further characterization of HL on cellular and molecular levels are emerging as tools for treatment stratification and predictors of disease status. Newer targeted therapies have emerged …
The incorporation of interim positron emission tomography (PET) imaging and, recently, further characterization of HL on cellular and molecu …
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
Russell J, Collins A, Fowler A, Karanth M, Saha C, Docherty S, Padayatty J, Maw K, Lentell I, Cooke L, Hodson A, Shah N, Sadullah S, Grigoropoulos N, Qian W, Kirkwood AA, Uttenthal BJ, Johnson P, Follows GA. Russell J, et al. Ann Hematol. 2021 Apr;100(4):1049-1058. doi: 10.1007/s00277-021-04460-9. Epub 2021 Feb 27. Ann Hematol. 2021. PMID: 33641019 Free PMC article.
Real-world eBEACOPP patients (n=44) had superior PFS (95.5%) compared with real-world ABVD (HR 0.20, p=0.027) and RATHL (HR 0.21, p=0.015), and superior OS for higher-risk (international prognostic score 3 [IPS 3+]) patients compared with real-world IPS 3+ ABVD (100% vs 84 …
Real-world eBEACOPP patients (n=44) had superior PFS (95.5%) compared with real-world ABVD (HR 0.20, p=0.027) and RATHL (HR 0.21, p=0.015), …
59 results